<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03994211</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-290-105</org_study_id>
    <secondary_id>2019-000112-28</secondary_id>
    <nct_id>NCT03994211</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer</brief_title>
  <official_title>A Phase 1, Open-label, Parallel-group, Fixed-sequence Study to Investigate the Effect of the CYP3A Inducer Rifampin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of Pamiparib (BGB-290) in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2-phase study in participants with advanced solid tumors. The first phase consists&#xD;
      of Part A and Part B. Part A will investigate the effect of rifampin on the pharmacokinetics&#xD;
      (PK) of pamiparib and Part B will investigate the effect of itraconazole in the PK of&#xD;
      pamiparib. Phase 2 will allow participants continued access to pamiparib after the PK phase&#xD;
      and will provide additional safety data.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 19, 2019</start_date>
  <completion_date type="Actual">August 7, 2021</completion_date>
  <primary_completion_date type="Actual">October 20, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration vs. time curve (AUC)</measure>
    <time_frame>up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax)</measure>
    <time_frame>up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal half-life (t1/2)</measure>
    <time_frame>up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent plasma clearance (CL/F)</measure>
    <time_frame>up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution (Vz/F)</measure>
    <time_frame>up to 13 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and severity of adverse effects</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of laboratory abnormalities</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead electrocardiogram (ECG) parameters</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examinations</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Assessment of the participant's general appearance, skin, thorax/lungs, cardiovascular, and abdomen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supine pulse rate</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body temperature</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Arm A (core phase)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (core phase)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Extension phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pamiparib (28 day cycles)</intervention_name>
    <description>60 mg administered orally twice daily/ 28day cycles</description>
    <arm_group_label>Extension phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pamiparib 60 mg</intervention_name>
    <description>single dose of 60 mg pamiparib orally in the fasted state (at least 8 hours predose)</description>
    <arm_group_label>Arm A (core phase)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pamiparib 20 mg</intervention_name>
    <description>single dose of 20 mg pamiparib orally in the fasted state (at least 8 hours predose)</description>
    <arm_group_label>Arm B (core phase)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>itraconazole</intervention_name>
    <description>200 mg itraconazole once a day approximately 30 minutes after completing a meal</description>
    <arm_group_label>Arm B (core phase)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifampin</intervention_name>
    <description>600 mg rifampin once a day in the fasted state (at least 2 hours predose)</description>
    <arm_group_label>Arm A (core phase)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Histologically or cytologically confirmed advanced or metastatic solid tumors that are&#xD;
             refractory or resistant to standard therapy or for which no suitable effective&#xD;
             standard therapy exists.&#xD;
&#xD;
          3. Disease that is evaluable per RECIST Version 1.1 or Prostate Cancer Working Group-3&#xD;
             (PCWG-3)&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 (Appendix 2)&#xD;
&#xD;
          5. Life expectancy ≥ 12 weeks&#xD;
&#xD;
          6. Adequate hematologic and end-organ function&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. History of hypersensitivity to rifampin, any rifamycin or any of the components of the&#xD;
             rifampin capsule (Part A).&#xD;
&#xD;
          2. History of hypersensitivity to itraconazole or any of the components of the&#xD;
             itraconazole capsule (Part B).&#xD;
&#xD;
          3. Prior treatment with a PARP inhibitor at therapeutic doses is allowed, provided that&#xD;
             such treatment was not the most recent therapy (PARP inhibitor must have been&#xD;
             discontinued ≥ 3 months prior to the first dose of pamiparib):&#xD;
&#xD;
             - Participants who experienced prior severe toxicity to PARP inhibitors that in the&#xD;
             opinion of the investigator precludes further treatment with PARP inhibitors should be&#xD;
             excluded&#xD;
&#xD;
          4. Diagnosis of Myelodysplastic syndrome (MDS)&#xD;
&#xD;
          5. Active infection requiring systemic treatment&#xD;
&#xD;
          6. Any of the following cardiovascular criteria:&#xD;
&#xD;
               1. Cardiac chest pain, defined as moderate pain that limits instrumental activities&#xD;
                  of daily living, ≤ 28 days before Day 1 of pamiparib administration&#xD;
&#xD;
               2. Symptomatic pulmonary embolism ≤ 28 days before Day 1 of pamiparib administration&#xD;
&#xD;
               3. Any history of acute myocardial infarction ≤ 6 months before Day 1 of pamiparib&#xD;
                  administration&#xD;
&#xD;
               4. Any history of heart failure meeting New York Heart Association Classification&#xD;
                  III or IV (Appendix 5) ≤ 6 months before Day 1 of pamiparib&#xD;
&#xD;
                  - Participants with congestive heart failure or history of heart failure should&#xD;
                  be excluded from Part B (itraconazole)&#xD;
&#xD;
               5. Any event of ventricular arrhythmia ≥ Grade 2 in severity ≤ 6 months before Day 1&#xD;
                  of pamiparib administration&#xD;
&#xD;
               6. Any history of cerebral vascular accident ≤ 6 months before Day 1 of pamiparib&#xD;
                  administration&#xD;
&#xD;
          7. Previous complete gastric resection or lap-band surgery, chronic diarrhea, active&#xD;
             inflammatory gastrointestinal disease, known diverticular disease or any other&#xD;
             disease-causing malabsorption syndrome&#xD;
&#xD;
             - Gastroesophageal reflux disease under treatment with proton pump inhibitors is&#xD;
             allowed&#xD;
&#xD;
          8. Active bleeding disorder, including gastrointestinal bleeding, as evidenced by&#xD;
             hematemesis, significant hemoptysis, or melena ≤ 6 months before Day 1 of pamiparib&#xD;
             administration&#xD;
&#xD;
          9. Use or anticipated need for food or drugs known to be strong or moderate CYP3A&#xD;
             inhibitors or strong CYP3A inducers ≤ 14 days (or ≤ 5 half-lives if half-life is&#xD;
             known) prior to Day 1 of pamiparib administration&#xD;
&#xD;
         10. Known history of intolerance to the excipients of the pamiparib capsule&#xD;
&#xD;
         11. Have known hereditary problems of galactose intolerance, the Lapp lactase deficiency&#xD;
             or glucose-galactose malabsorption&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katie Wood</last_name>
    <role>Study Director</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute of Clinical Medicine</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Hospital, Oncology Department</name>
      <address>
        <city>Chisinau</city>
        <zip>2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital LuxMed</name>
      <address>
        <city>Warsaw</city>
        <zip>02-801</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Clinical Research, s.r.o.</name>
      <address>
        <city>Bratislava</city>
        <zip>83101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Georgia</country>
    <country>Moldova, Republic of</country>
    <country>Poland</country>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 18, 2019</study_first_submitted>
  <study_first_submitted_qc>June 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2019</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

